4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,630,220 | -22.9% | 363,725 | +9.4% | 0.00% | 0.0% |
Q2 2023 | $6,005,871 | +27.3% | 332,367 | +21.1% | 0.00% | 0.0% |
Q1 2023 | $4,717,434 | -22.7% | 274,429 | -0.1% | 0.00% | 0.0% |
Q4 2022 | $6,103,774 | +174.5% | 274,821 | -0.7% | 0.00% | 0.0% |
Q3 2022 | $2,224,000 | +16.1% | 276,680 | +0.9% | 0.00% | – |
Q2 2022 | $1,915,000 | -51.1% | 274,331 | +5.8% | 0.00% | -100.0% |
Q1 2022 | $3,920,000 | -29.8% | 259,280 | +1.9% | 0.00% | 0.0% |
Q4 2021 | $5,581,000 | +9.0% | 254,372 | +34.0% | 0.00% | 0.0% |
Q3 2021 | $5,119,000 | +115.6% | 189,825 | +92.7% | 0.00% | – |
Q2 2021 | $2,374,000 | -37.2% | 98,528 | +13.1% | 0.00% | -100.0% |
Q1 2021 | $3,780,000 | – | 87,143 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 831,267 | $22,419,000 | 5.52% |
Aquilo Capital Management, LLC | 1,099,944 | $29,665,000 | 5.39% |
BVF INC/IL | 2,005,862 | $54,098,000 | 2.11% |
Casdin Capital, LLC | 1,115,455 | $30,084,000 | 0.75% |
Soleus Capital Management, L.P. | 120,900 | $3,261,000 | 0.51% |
Eagle Health Investments LP | 57,090 | $1,540,000 | 0.49% |
Centiva Capital, LP | 358,863 | $7,220,000 | 0.45% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $106,206,000 | 0.29% |
ArrowMark Colorado Holdings LLC | 1,003,447 | $27,063,000 | 0.21% |
Perceptive Advisors | 375,256 | $10,121,000 | 0.15% |